Anne Nunes's Insider Trades & SAST Disclosures
Anne Nunes's most recent trade in Anika Therapeutics Inc. was a trade of 20,761 Restricted Stock Unit done . Disclosure was reported to the exchange on March 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Anne Nunes.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 20,761 | 20,761 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 4,650 | 4,650 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 3,637 | 7,275 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 3,637 | 21,722 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.91 per share. | 14 Mar 2025 | 1,068 | 20,654 (0%) | 0% | 15.9 | 16,992 | Common Stock |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2025 | 2,561 | 18,837 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2025 | 2,561 | 0 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.79 per share. | 11 Mar 2025 | 752 | 18,085 (0%) | 0% | 16.8 | 12,626 | Common Stock |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 3,296 | 17,235 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 3,296 | 3,295 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.62 per share. | 10 Mar 2025 | 959 | 16,276 (0%) | 0% | 16.6 | 15,939 | Common Stock |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 2,491 | 14,211 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 2,491 | 0 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.27 per share. | 01 Oct 2024 | 732 | 13,479 (0%) | 0% | 24.3 | 17,766 | Common Stock |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 26,442 | 26,442 | - | - | Stock Option (Right to Buy) | |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 10,912 | 10,912 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 3,295 | 6,591 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 3,295 | 10,245 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 2,561 | 2,561 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 2,561 | 11,838 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.42 per share. | 11 Mar 2024 | 968 | 9,277 (0%) | 0% | 25.4 | 24,607 | Common Stock |
| Anika Therapeutics Inc. | Anne Nunes | SVP, Chief Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.79 per share. | 11 Mar 2024 | 752 | 11,086 (0%) | 0% | 25.8 | 19,394 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges